Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 12.05 NOK
Change Today +0.65 / 5.70%
Volume 52.1K
As of 10:25 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

pci biotech holding asa (PCIB) Snapshot

Open
11.55 NOK
Previous Close
11.40 NOK
Day High
12.05 NOK
Day Low
11.20 NOK
52 Week High
05/6/14 - 29.91 NOK
52 Week Low
12/17/14 - 9.45 NOK
Market Cap
177.5M
Average Volume 10 Days
19.4K
EPS TTM
-3.99 NOK
Shares Outstanding
14.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PCI BIOTECH HOLDING ASA (PCIB)

Related News

No related news articles were found.

pci biotech holding asa (PCIB) Related Businessweek News

No Related Businessweek News Found

pci biotech holding asa (PCIB) Details

PCI Biotech Holding ASA, an oncology-focused company, develops therapeutic products based on its proprietary photochemical internalization (PCI) technology. Its PCI technology induces triggered endosomal release, which enhances the therapeutic potential of various modalities, such as small molecules, ADCs, and siRNA. The company’s clinical study programs include phase II study of Amphinex based PCI with bleomycin to treat head and neck cancer; phase I/II study of Amphinex induced PCI of gemcitabine to treat bile duct cancer; and preclinical study of Cytotoxic T Lymphocytes for use in the treatment of cancers and other infectious diseases. It is also involved in the preclinical study on the delivery of macromolecules, such as proteins and nucleic acids; vaccine antigens; drugs carried by antibodies; and nanoparticles, as well as some small molecule drugs. The company has a pre-clinical research collaboration agreement with RXi Pharmaceuticals to explore potential synergies. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Lysaker, Norway.

11 Employees
Last Reported Date: 03/24/15
Founded in 2000

pci biotech holding asa (PCIB) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: 1.6M NOK
Chief Financial Officer
Total Annual Compensation: 237.0K NOK
Compensation as of Fiscal Year 2013.

pci biotech holding asa (PCIB) Key Developments

PCI Biotech Initiates Pre-Clinical Research Collaboration in RXi Pharmaceuticals

PCI Biotech announced that it is initiating a pre-clinical research collaboration with RXi Pharmaceuticals. The partnership is governed by a pre-clinical research collaboration agreement. Initially, the purpose of the pre-clinical research collaboration is to utilize the companies' complementary scientific platforms to explore potential synergies. In brief the pre-clinical research collaboration will evaluate technology compatibility based on in vitro and in vivo studies. The costs related to the research collaboration will be covered by each company separately. The companies will evaluate results achieved from this research collaboration and then explore the potential for a closer collaboration. Both companies will retain exclusive ownership rights to existing registered intellectual property. However, any inventions arising from the collaboration will be jointly owned by the companies.

PCI Biotech Holding ASA Reports Consolidated and Standalone Earnings Results for the Year Ended December 31, 2014

PCI Biotech Holding ASA reported consolidated and standalone earnings results for the year ended December 31, 2014. For the year, the company reported consolidated total income of NOK 7.297 million compared to NOK 6.681 million a year ago. Operating loss was NOK 36.472 million compared to NOK 29.325 million a year ago. Ordinary loss before taxes was NOK 35.840 million compared to NOK 27.608 million a year ago. Net loss for the year was NOK 35.840 million compared to NOK 27.608 million a year ago. Loss per basic and diluted share was NOK 4.64 compared to NOK 3.59 a year ago. Cash flow from operating activities were NOK 31.674 million compared to NOK 28.593 million a year ago. For the year, the company reported standalone operating loss was NOK 2.996 million compared to NOK 2.243 million a year ago. Ordinary loss before taxes was NOK 30.904 million compared to NOK 1.183 million a year ago. Net loss for the year was NOK 30.904 million compared to NOK 1.183 million a year ago. Cash flow from operating activities were NOK 2.941 million compared to NOK 2.367 million a year ago.

PCI Biotech Holding ASA Reports Consolidated Earnings Results for the Fourth Quarter and Full Year December 31, 2014

PCI Biotech Holding ASA reported consolidated earnings results for the fourth quarter and full year December 31, 2014. For the quarter, the company reported other income of NOK 1.54 million compared to NOK 1.98 million a year ago. Operating loss was NOK 10.27 million compared to NOK 9.32 million a year ago. Ordinary loss before taxes was NOK 10.21 million compared to NOK 8.85 million a year ago. Net loss was NOK 10.21 million compared to NOK 8.85 million a year ago. Net cash flow used in operations was NOK 3.89 million compared to NOK 5.93 million a year ago. For the year, the company reported turnover of NOK 7.30 million compared to NOK 6.68 million a year ago. Operating loss was NOK 36.47 million compared to NOK 29.33 million a year ago. Ordinary loss before taxes was NOK 35.84 million compared to NOK 27.61 million a year ago. Net loss was NOK 35.84 million compared to NOK 27.61 million a year ago. Net cash flow used in operations was NOK 30.84 million compared to NOK 26.88 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCIB:NO 12.05 NOK +0.65

PCIB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PCIB.
View Industry Companies
 

Industry Analysis

PCIB

Industry Average

Valuation PCIB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.9x
Price/Book 9.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PCI BIOTECH HOLDING ASA, please visit www.pcibiotech.no. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.